Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A16 | Q86VW1 | 1/20 | 0.42 |
| ▸ | CPT2 | P23786 | 1/20 | 0.40 |
| ▸ | CPT1A | P50416 | 1/20 | 0.40 |
| ▸ | CRAT | P43155 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | CA4 | P22748 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL3680487 | 0.79 | SLC22A16 (0.64) | SLC22A16CPT2CPT1ACRATMEN1 | |
| SCHEMBL3668709 | 0.79 | SLC22A16 (0.64) | SLC22A16CPT2CPT1ACRATMEN1 | |
| Hydrochloric Acid SCHEMBL3675692 | 0.78 | SLC22A16 (0.62) | SLC22A16CPT2CPT1ACRATMEN1 | |
| SCHEMBL3669963 | 0.78 | SLC22A16 (0.42) | SLC22A16CPT2CPT1ACRATMEN1 | |
| SCHEMBL6664365 | 0.78 | SLC22A16 (0.42) | SLC22A16CPT2CPT1ACRATMEN1 | |
| Sulfuric Acid SCHEMBL3672616 | 0.74 | SLC22A16 (0.56) | SLC22A16CPT2CPT1ACRATMEN1 | |
| SCHEMBL3677887 | 0.73 | MEN1 (0.68) | SLC22A16CPT2CPT1ACRATMEN1 | |
| SCHEMBL3676901 | 0.70 | MEN1 (0.41) | SLC22A16CPT2CPT1ACRATMEN1 | |
| Carnitine SCHEMBL27673497 | 0.67 | SLC22A16 (0.83) | SLC22A16CPT2CPT1ACRATMEN1 | |
| Carnitine SCHEMBL31299810 | 0.64 | SLC22A16 (0.77) | SLC22A16CPT2CPT1ACRATMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7714166-B2 | Process for producing carnitinamide | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2010-05-11 | — | — | US | disclosed |
| US-20090143616-A1 | Process for Producing Carnitinamide | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2009-06-04 | — | — | US | disclosed |
| CN-101304965-A | Process for producing carnitinamide | MITSUBISHI GAS CHEMICAL CO (JP) | 2008-11-12 | — | — | CN | disclosed |
| EP-1930314-A1 | PROCESS FOR PRODUCING CARNITINAMIDE | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2008-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143616-A1 | Process for Producing Carnitinamide | CRAT, NISCH, NAAA | SLC22A16 904/4885CPT2 5/4885CPT1A 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.